Project TitleGene Therapy for Atrial Fibrillation
Track Code2013-181
Short Description

Novel gene therapy for atrial fibrillation (AF) targeting molecular mechanisms underlying disease development

#therapeutics #genetherapy #cardiology #biomedical


A Northwestern researcher has developed a new therapeutic approach for atrial fibrillation (AF) by attacking the molecular mechanisms that cause AF. This approach utilizes gene therapy to inhibit reactive oxygen species (ROS) in the atrium of the heart, by downregulating an enzyme that drives their production. Current AF therapies use an anatomic approach, which has a 50-60% efficacy rate. A common issue with current treatment methods is an induction of arrhythmias. This new gene therapy does not induce arrhythmias and can even be used in patients with underlying structural heart disease. Gene therapy for AF is potentially a stand-alone treatment; however, using it in combination with other treatment modalities may dramatically increase their effectiveness.

Tagsbiomedical, cardiology, THERAPEUTICS: gene therapy
Posted DateJun 3, 2015 10:58 AM


Rishi Arora*


  • AF therapy  
  • Research tool


  • Targets reactive oxygen species that cause AF
  • Improves treatment options for AF patients with structural heart disease


IP Status

US and international patent applications have been filed.

Contact Information

Michael Moore, PhD

Invention Manager

(p) 847.491.4645